Transform Your Pharma Operations with AI-Powered Intelligence. Experience how Leucine's integrated platform brings together manufacturing, quality, and laboratory operations in one digital ecosystem. Schedule a personalized demo to see how our AI solutions can optimize your processes, ensure compliance, and drive operational excellence.
See How AI Transforms Your Shop Floor Operations.
Experience firsthand how Leucine's 10x MES digitalizes batch records, streamlines production, and provides real-time monitoring of your manufacturing operations. Schedule a personalized demo to discover how our AI-powered platform can enhance your productivity while maintaining compliance.
Experience AI-Driven Quality Management in Action.
See how Leucine's 10x QMS automates compliance workflows, streamlines change control, and ensures regulatory adherence. Schedule a demo to learn how our AI-powered platform can help you manage quality processes more efficiently while reducing compliance risks.
Discover Smart Laboratory Operations Management.
Watch how Leucine's 10x LES orchestrates your lab operations, automates documentation, and ensures data integrity. Schedule a demo to see how our AI-powered platform can accelerate your testing processes while maintaining audit-readiness.
Explore essential insights on batch release processes to enhance compliance and quality. Dive into our article for practical guidance and best practices.

| TITLE/ COMPANY | Issue Date | Status | Details |
|---|---|---|---|
| Copies of Approved or Indexed Products: Mixlab WI LLC |
01 May 2026 | Normal | Justification: Efficient and complete documentation is critical for transparency and accountability in pharmaceutical processes. Excerpt: Records for the prescriber’s medical rationale do not describe why the approved drug is unacceptable or unsafe. View Details |
| Your firm does not have adequate systems and processes to enable compliance with the verification requirements of section 582(c) of Federal Food, Drug, and Cosmetic Act VET4U, LLC |
11 Mar 2026 | Normal | Justification: Document Management is linked due to inadequate documentation for identifying and handling suspect products as per DSCSA. Excerpt: Your Quality Document 390, titled Suspect Product, last reviewed on 06/02/2025, does not establish adequate systems and processes... View Details |
| The responsibilities and procedures applicable to the quality control unit are not fully followed. Maiva Pharma Private Limited |
20 Feb 2026 | Normal | Justification: Document Management is linked because the issue arises from improper handling and control of document destruction logs. Excerpt: However, during review of the Shredding Machine Usage Logbook, it was observed that the individual who performed the document destruction also signed as the verifier. View Details |
| Production records do not contain complete information relating to the production and control of each batch Maiva Pharma Private Limited |
20 Feb 2026 | Normal | Justification: The observation details the absence of a structured document control system, indicating improper management of original CGMP records. Excerpt: These documents were not marked as copies, voided through an established procedure, or otherwise reconciled as part of an approved document control system. View Details |
| There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed. Aurobindo Pharma Limited, Unit VII |
10 Feb 2026 | Normal | Justification: Inconsistencies in document issuance procedures indicate issues within the Document Management process. Excerpt: Two copies of the Line Clearance Checklist were issued when only one was required. View Details |
View and learn more about FDA Inspections
with our comprehensive list of resources